The current shareholder, Charba, has continued to invest, with the participation of the Dutch ponds, the Thai Qhua, the In-In-In-In-Integrated Fund and the State of Thailand.

On 15 May, a recent announcement was made by Nanjing Yukio Takasu, Inc. (known as “Red Yunus”, that nearly 100 million yuan renminbi B+ swaps had been completed, co-sponsored by the Dutch ponds, the Gulf of Guinea in Thailand, the Ingion Fund and the State of Thailand Astronomical Fund, with ongoing investments by existing shareholders in Chariba. The fund will simultaneously develop a new generation of EGFR inhibitors H002 in China and the United States for clinical trials in non-small cell pulmonary cancers, while accelerating the development of pipelines and technology based on a unique structural pharmacological platform based on mangroves. Mangune is a clinical phase of small molecular innovation research and development, with structural pharmacology at the core, integrating molecular mocking, chemistry and artificial intelligent (AI). Mange clouds have accumulated unique structural biology data and algorithmic models in several clinical demand-oriented areas, and have set up a number of molecules for drug development and pipelines that cover tumours, rare diseases and other treatments with highly unmet clinical needs. Currently, H002, a company-owned, entirely new molecular drug, is conducting a clinical test study in the Central American region, which is expected to be the best option for the next generation of EGFR-TKI inhibitors. At the same time, the company’s first inclination project on multiple tumours, such as breast cancer, has entered the PCC phase and is expected to declare clinical in 2024.